The Effect of Protein-enriched Diet on Body Composition and Appetite (ProteinRich)
Obesity is a major problem worldwide and current dietary interventions are not proving to be enough to cease the increase in levels of obesity and its detrimental side effects, such as nonalcoholic fatty liver disease (NAFLD).
Existing data suggests that adjustments in the macronutrient composition of the diet, more specifically the protein content, may have beneficial effects on body composition and an antiobesegenic effect on appetite. This may be important in terms of controlling body weight and reducing the amount of fatty tissue within our bodies and organs, and therefore preventing obesity and its health related side effects.
The investigators will perform a study to investigate whether a high protein low energy diet compared to a normal protein low energy diet, in overweight adults can modify appetite and aid loss of weight and fat mass. Subjects will receive either a high protein low energy diet (1.34g protein/kg body weight) or a normal protein low energy diet (0.8g protein/kg body weight) in the form of 2 meal replacements and one conventional meal per day with 2 snacks for 12 weeks.
HYPOTHESIS In overweight subjects with the metabolic syndrome, a 12 week dietary intervention with a high protein low energy diet will lead to a reduced appetite, body weight and fat mass, more specifically to a greater fall in levels of fat in the liver and pancreas than a low energy normal protein diet.
研究概览
研究类型
注册 (实际的)
阶段
- 不适用
联系人和位置
学习地点
-
-
-
London、英国、W12 0NN
- Imperial College London
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Overweight and obese people as classified by BMI 27-35kg/ m2 (inclusive)
- A Finnish Diabetes Risk Score (FINDRISC) >8 [22]
- Waist circumference measurement of ≥102cm in males or ≥88cm in females
- Assessed as appropriate for inclusion, based on a prestudy screening (see section 3.4)
- Willingness and ability to give written informed consent and willingness and ability to understand, to participate and to comply with the study requirements
Exclusion Criteria:
- Claustrophobia
- Pacemaker, metal implant, clips, implanted device, shrapnel or bullets, metal in eyes that precludes magnetic resonance imaging
- Treatment with any medication that might affect the study outcome (e.g., medication that is affecting appetite regulation and/or blood flow)
- Current pregnancy or breast feeding
- Delivery within the last year
- Bariatric surgery
- History of any disease with unknown outcome
- Significant intercurrent disease or history of clinically significant disease of any type, in particular liver, kidney, or heart disease, any form of diabetes mellitus or psychiatric illness (including Depression as defined by BDIII score above 28)
- History of cancer, excluding skin cancer
- History of severe or multiple allergies, severe adverse drug reaction or leucopenia
- Smokers
- Regular drinkers of more than three units of alcohol daily (1 unit = 300 ml beer, 1 glass wine, 1 measure spirit)
- Subjects who have had a fluctuation of body weight >5% in the 3 months prior to entering into the study
- History of, or current evidence of, abuse of alcohol or any drug substance, licit or illicit
- Regular intake of overthecounter (OTC) medication (other than the occasional paracetamol/aspirin)
- Poor compliers or subjects unlikely to attend
- Blood donation within the 12 week period before the initial study dose
学习计划
研究是如何设计的？
设计细节
- 主要用途：治疗
- 分配：随机化
- 介入模型：并行分配
- 屏蔽：三倍
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的：High protein low calorie meal replacements
Meal replacements with added protein powder(1.34g
pro/kg).
|
The high protein group will have meal replacements with added protein powder (to achieve 1.34g protein/kg body weight) and the control group will have standard meal replacements (0.8g protein/kg body weight).
Meal replacements have been used in hundreds of previous human studies and are generally not found to be linked to any serious adverse effects.
|
|
假比较器：Normal protein, low calorie meal replacement group
The control group will have standard meal replacements (0.8g protein/kg body weight).
|
The high protein group will have meal replacements with added protein powder (to achieve 1.34g protein/kg body weight) and the control group will have standard meal replacements (0.8g protein/kg body weight).
Meal replacements have been used in hundreds of previous human studies and are generally not found to be linked to any serious adverse effects.
|
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in Lipid Content of the Liver (Intrahepatocellular Lipid)
大体时间：Change from Baseline at 12 weeks
|
Changes in body weight and body composition, more specifically visceral, muscle, liver and pancreas fat content will be measured using magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS).
Individual's data will be compared at baseline and at 12 weeks of following the diet and also to that of the participants given normal protein low energy diets.
This data may therefore support our hypothesis that high protein intakes may help to aid weight loss and reduce fat mass and would therefore be a viable option in the treatment of obesity.
|
Change from Baseline at 12 weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in Appetite Regulation, Measured by VAS and Food Intake.
大体时间：Baseline and 12 weeks
|
It has also been suggested that highprotein diets are more beneficial in the regulation of appetite.
We therefore aim to measure any changes in appetite whilst on a highprotein lowenergy diet compared to a normalprotein lowenergy diet.
Changes in appetite will be measured using validated questionnaires assessing subjects feeling of hunger, pleasantness and volume able to eat as well as fullness.
This data may support our hypothesis that highprotein intakes may alter appetite regulation and therefore be a useful in the treatment of obesity.
|
Baseline and 12 weeks
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Composite Appetite Score AUC (Area Under Curve)
大体时间：Baseline and 12 weeks
|
A composite appetite score was calculated combing all four appetite measures to give a summary measure of appetite. Each appetite measure was assessed using validated 100 mm visual analogue scales (VAS) for hunger, fullness, desire to eat, and prospective food consumption (PFC) with the most positive and most negative sensations anchoring opposite ends of the line, from 'Not at all' or 'Nothing' to 'Extremely' or 'A large amount'. Participants were asked to mark the line at the point corresponding to their perceived appetite at that time. There is no score which is better or worse. Composite Appetite score (mm min) = [desire to eat + hunger + (100 - fullness) + prospective consumption]/4, as described by (Anderson et al, 2002). This reflects the four appetite related VAS (visual analogue scale) questions and was used as a summary measure of appetite. Area Under the Curve (AUC) was calculated for composite appetites score using the trapezoidal rule. AUC scores range from 0-9000mm*min |
Baseline and 12 weeks
|
合作者和调查者
调查人员
- 首席研究员：Gary Frost、Imperial College London
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.